VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | How MRD assessment can inform treatment decisions in AML

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares some insights into how measurable residual disease (MRD) assessment can inform treatment decisions in acute myeloid leukemia (AML), highlighting the importance of MRD as a predictive marker for long-term survival and as a method of evaluating the efficiency of therapeutic agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter